{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:02:11Z","timestamp":1785074531120,"version":"3.55.0"},"reference-count":264,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189603","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:53Z","timestamp":1778284853000},"page":"189603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role and therapeutic potential of protein glycosylation in the immune regulation of breast cancer"],"prefix":"10.1016","volume":"1881","author":[{"given":"Caiqi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0015","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0020","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0025","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0030","first-page":"524","article-title":"Breast Cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0035","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0040","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s10147-024-02570-8","article-title":"Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022","volume":"29","author":"Nozawa","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0045","first-page":"132","article-title":"Chemotherapy on hematological and biochemical parameters in breast cancer patients","volume":"16","author":"Pullakanam","year":"2025","journal-title":"Caspian J. Intern. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0050","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1210\/en.2010-0782","article-title":"KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells","volume":"152","author":"Beyer","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbcan.2026.189603_bb0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2019.00344","article-title":"Molecular insights into the relationship between autoimmune thyroid diseases and breast cancer: a critical perspective on autoimmunity and ER stress","volume":"10","author":"Rahman","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.sbi.2011.08.005","article-title":"Mechanisms and principles of N-linked protein glycosylation","volume":"21","author":"Schwarz","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108149","article-title":"Aberrant protein glycosylation: implications on diagnosis and immunotherapy","volume":"66","author":"Bangarh","year":"2023","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188464","article-title":"Altered glycosylation in cancer: a promising target for biomarkers and therapeutics","volume":"1875","author":"Thomas","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0075","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.7150\/thno.81760","article-title":"Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics","volume":"13","author":"\u010caval","year":"2023","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0080","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cac2.12610","article-title":"Altered glycosylation in cancer: molecular functions and therapeutic potential","volume":"44","author":"Xu","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.2012.06517.x","article-title":"Multifarious roles of sialic acids in immunity","volume":"1253","author":"Varki","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189603_bb0095","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1182\/blood-2010-12-326074","article-title":"Protein O-fucosyltransferase 1 (Pofut1) regulates lymphoid and myeloid homeostasis through modulation of notch receptor ligand interactions","volume":"117","author":"Yao","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0092-8674(01)00277-X","article-title":"Glycosylation, immunity, and autoimmunity","volume":"104","author":"Lowe","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189603_bb0105","doi-asserted-by":"crossref","first-page":"1088560","DOI":"10.3389\/fimmu.2022.1088560","article-title":"B7 family protein glycosylation: promising novel targets in tumor treatment","volume":"13","author":"Xiao","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0110","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/JS9.0000000000002164","article-title":"Loss of RPN1 promotes antitumor immunity via PD-L1 checkpoint blockade in triple-negative breast cancer - experimental studies","volume":"111","author":"Wang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.bbcan.2026.189603_bb0115","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast Cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41401-024-01419-0","article-title":"STT3-mediated aberrant N-glycosylation of CD24 inhibits paclitaxel sensitivity in triple-negative breast cancer","volume":"46","author":"Wang","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s13046-024-03236-z","article-title":"From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment","volume":"43","author":"Hulahan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2022.05.006","article-title":"Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer","volume":"33","author":"Van Baelen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular classification of breast cancer: relevance and challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab Med."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189603_bb0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0165","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0175","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0190","first-page":"924","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Can."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0200","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189603_bb0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semcancer.2017.03.002","article-title":"Role of protein glycosylation in cancer metastasis","volume":"44","author":"Oliveira-Ferrer","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","article-title":"Targeting glycosylation: a new road for cancer drug discovery","volume":"6","author":"Costa","year":"2020","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0220","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0225","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbagen.2014.03.016","article-title":"A guide into glycosciences: how chemistry, biochemistry and biology cooperate to crack the sugar code","volume":"1850","author":"Sol\u00eds","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbagen.2014.05.003","article-title":"Mucins: a biologically relevant glycan barrier in mucosal protection","volume":"1850","author":"Corfield","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrd1751","article-title":"Glycans in cancer and inflammation--potential for therapeutics and diagnostics","volume":"4","author":"Dube","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0240","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","article-title":"Glycosylation in health and disease","volume":"15","author":"Reily","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0245","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","article-title":"Global view of human protein glycosylation pathways and functions","volume":"21","author":"Schjoldager","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0250","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1016\/j.cub.2019.01.003","article-title":"Protein glycosylation","volume":"29","author":"Eichler","year":"2019","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.biochem.69.1.69","article-title":"Protein glucosylation and its role in protein folding","volume":"69","author":"Parodi","year":"2000","journal-title":"Annu. Rev. Biochem."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0260","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41569-024-00998-z","article-title":"Protein glycosylation in cardiovascular health and disease","volume":"21","author":"Chatham","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41419-023-05733-z","article-title":"The role of N-glycosylation modification in the pathogenesis of liver cancer","volume":"14","author":"Hu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0270","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41467-024-44960-6","article-title":"EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses","volume":"15","author":"Pan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189603_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.acc.2018.12.005","article-title":"Glycosylation markers in cancer","volume":"89","author":"Silsirivanit","year":"2019","journal-title":"Adv. Clin. Chem."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189603_bb0280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41388-023-02702-w","article-title":"Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications","volume":"42","author":"Wang","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-016-0334-6","article-title":"Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma","volume":"9","author":"Ho","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0290","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13058-017-0904-8","article-title":"FUT8 promotes breast cancer cell invasiveness by remodeling TGF-\u03b2 receptor core fucosylation","volume":"19","author":"Tu","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0295","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1541-7786.MCR-25-0483","article-title":"Fucosylated N-glycan landscape of triple-negative breast Cancer","volume":"23","author":"Scott","year":"2025","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0300","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189603_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.962908","article-title":"ST6Gal1: oncogenic signaling pathways and targets","volume":"9","author":"Gc","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0310","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0315","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","article-title":"Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2019.05.017","article-title":"An atlas of human glycosylation pathways enables display of the human Glycome by gene engineered cells","volume":"75","author":"Narimatsu","year":"2019","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189239","article-title":"A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer","volume":"1880","author":"Eggermont","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189603_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893365","article-title":"N-glycosylation and inflammation; the not-so-sweet relation","volume":"13","author":"Radovani","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0335","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/1541-7786.MCR-21-0348","article-title":"N-glycosylation patterns correlate with hepatocellular carcinoma genetic subtypes","volume":"19","author":"DelaCourt","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0009-8981(92)90073-Y","article-title":"N-glycosylation of serum proteins in disease and its investigation using lectins","volume":"208","author":"Turner","year":"1992","journal-title":"Clin. Chim. Acta"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0345","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/s41418-023-01188-z","article-title":"Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma","volume":"30","author":"Ma","year":"2023","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0350","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13046-018-0935-8","article-title":"Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation","volume":"37","author":"Wu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0355","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.apsb.2023.10.014","article-title":"The role of N-glycosylation in cancer","volume":"14","author":"Lin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0360","article-title":"N-glycosylation modification of CTSD affects liver metastases in colorectal cancer","volume":"12","author":"Xiong","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0365","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2022.11.018","article-title":"N-glycosylation regulates intrinsic IFN-\u03b3 resistance in colorectal cancer: implications for immunotherapy","volume":"164","author":"Krug","year":"2023","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189603_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002699","article-title":"PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy","volume":"9","author":"Xu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189603_bb0375","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0380","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0385","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189274","article-title":"Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies","volume":"1880","author":"Granica","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0400","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"7559","key":"10.1016\/j.bbcan.2026.189603_bb0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0415","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-025-02330-w","article-title":"N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1","volume":"24","author":"Kaufman","year":"2025","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0420","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0425","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114851119","article-title":"D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0430","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1038\/s41467-023-42883-2","article-title":"Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer","volume":"14","author":"Ren","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0435","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0440","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.33249","article-title":"Novel insights into the function of CD24: a driving force in cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0445","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1535-7163.MCT-18-0292","article-title":"Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer","volume":"18","author":"Chan","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2014.06.022","article-title":"Enriched CD44(+)\/CD24(\u2212) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)","volume":"353","author":"Ma","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189603_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216724","article-title":"CD24 negativity reprograms mitochondrial metabolism to PPAR\u03b1 and NF-\u03baB-driven fatty acid \u03b2-oxidation in triple-negative breast cancer","volume":"587","author":"Murthy","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189603_bb0460","article-title":"Elucidating the multifaceted role of MGAT1 in hepatocellular carcinoma: integrative single-cell and spatial transcriptomics reveal novel therapeutic insights","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438935","article-title":"Role of glycosylation-related gene MGAT1 in pancreatic ductal adenocarcinoma","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0470","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41467-025-58524-9","article-title":"MGAT1-guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer","volume":"16","author":"Chi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189603_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100964","article-title":"The role of O-glycosylation in human disease","volume":"79","author":"Magalh\u00e3es","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.bbcan.2026.189603_bb0480","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","article-title":"Protein glycosylation in cancer","volume":"10","author":"Stowell","year":"2015","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0485","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/glycob\/cwr182","article-title":"Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family","volume":"22","author":"Bennett","year":"2012","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0490","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1074\/jbc.H117.812826","article-title":"Pleiotropic effects of O-glycosylation in colon cancer","volume":"293","author":"Zhang","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"39","key":"10.1016\/j.bbcan.2026.189603_bb0495","doi-asserted-by":"crossref","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","article-title":"Immature truncated O-glycophenotype of cancer directly induces oncogenic features","volume":"111","author":"Radhakrishnan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb0500","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1530\/ERC-16-0569","article-title":"Glycosylation is a global target for androgen control in prostate cancer cells","volume":"24","author":"Munkley","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189603_bb0505","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/pros.22826","article-title":"Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers","volume":"74","author":"Chen","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0510","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.1038\/s41598-023-43019-8","article-title":"The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer","volume":"13","author":"Hodgson","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189603_bb0515","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12935-020-01209-8","article-title":"miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR\/PI3K\/AKT pathway","volume":"20","author":"Cao","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0520","article-title":"Comprehensive pan-cancer analysis reveals the versatile role of GALNT7 in epigenetic alterations and immune modulation in cancer","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0525","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41388-023-02604-x","article-title":"Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth","volume":"42","author":"Scott","year":"2023","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0530","first-page":"198","article-title":"The role of GALNT7 as a potential diagnostic marker in prostate cancer","volume":"20","author":"Masone","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0535","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tan.12900","article-title":"Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen","volume":"88","author":"Fu","year":"2016","journal-title":"Hla"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13287-023-03334-3","article-title":"Side population cells derived from hUCMSCs and hPMSCs could inhibit the malignant behaviors of Tn(+) colorectal cancer cells from modifying their O-glycosylation status","volume":"14","author":"Hu","year":"2023","journal-title":"Stem Cell Res. Ther."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189603_bb0545","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70279","article-title":"Targeting Tn antigen suppresses aberrant O-glycosylation-elicited metastasis in breast cancer","volume":"28","author":"Du","year":"2024","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0550","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/jcmm.14740","article-title":"Cosmc overexpression enhances malignancies in human colon cancer","volume":"24","author":"Gao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189603_bb0555","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.7150\/ijbs.73431","article-title":"GALNT1 enhances malignant phenotype of gastric cancer via modulating CD44 glycosylation to activate the Wnt\/\u03b2-catenin signaling pathway","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2026.189603_bb0560","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/CMAR.S234735","article-title":"Cosmc disruption-mediated aberrant O-glycosylation suppresses breast cancer cell growth via impairment of CD44","volume":"12","author":"Du","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0565","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1158\/0008-5472.CAN-09-3911","article-title":"Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis","volume":"70","author":"Park","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0570","first-page":"581","article-title":"The GALNT6-LGALS3BP axis promotes breast cancer cell growth","volume":"56","author":"Kimura","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0575","doi-asserted-by":"crossref","first-page":"11794","DOI":"10.18632\/aging.103349","article-title":"GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of \u03b12M","volume":"12","author":"Liu","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189603_bb0580","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.neo.2018.08.006","article-title":"Critical role of estrogen receptor alpha O-glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells","volume":"20","author":"Deng","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189603_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111942","article-title":"GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma","volume":"134","author":"Chong","year":"2025","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0590","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12935-024-03492-1","article-title":"GALNT6 promotes bladder cancer malignancy and immune escape by epithelial-mesenchymal transition and CD8(+) T cells","volume":"24","author":"Sun","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0595","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s41388-019-1146-2","article-title":"LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity","volume":"39","author":"Fang","year":"2020","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189603_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133489","article-title":"GALNT1 expression is associated with angiogenesis and is a prognostic biomarker for breast cancer in adolescents and young adults (AYA)","volume":"15","author":"Oshi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0605","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1457598","article-title":"Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab","volume":"7","author":"Jabeen","year":"2018","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0610","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ccell.2025.05.003","article-title":"The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets","volume":"43","author":"Knol","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.bbcan.2026.189603_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1482929","article-title":"Bioinformatics insights into the role of GFPT1 in breast invasive carcinoma: implications for tumor prognosis, immune modulation, and therapeutic applications","volume":"15","author":"Liang","year":"2024","journal-title":"Front. Genet."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0620","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0625","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1186\/s12885-024-12811-8","article-title":"GFPT1 accelerates immune escape in breast cancer by modifying PD-L1 via O-glycosylation","volume":"24","author":"Tang","year":"2024","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0630","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0635","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41419-021-04028-5","article-title":"C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1","volume":"12","author":"Ou","year":"2021","journal-title":"Cell Death Dis."},{"issue":"44","key":"10.1016\/j.bbcan.2026.189603_bb0640","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408354121","article-title":"O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer","volume":"121","author":"Zhu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0645","doi-asserted-by":"crossref","first-page":"41r","DOI":"10.1093\/glycob\/cwg054","article-title":"Fucose: biosynthesis and biological function in mammals","volume":"13","author":"Becker","year":"2003","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0650","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biom2010034","article-title":"Fucosylation is a promising target for cancer diagnosis and therapy","volume":"2","author":"Miyoshi","year":"2012","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0655","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jb\/mvn011","article-title":"Biological function of fucosylation in cancer biology","volume":"143","author":"Miyoshi","year":"2008","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010455","article-title":"FUT8 alpha-(1,6)-Fucosyltransferase in cancer","volume":"22","author":"Bastian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4\u20135","key":"10.1016\/j.bbcan.2026.189603_bb0665","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10719-024-10167-6","article-title":"RACK1 inhibits ferroptosis of cervical cancer by enhancing SLC7A11 core-fucosylation","volume":"41","author":"Yan","year":"2024","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.bbcan.2026.189603_bb0670","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jprot.2015.11.006","article-title":"Increased \u03b11-3 fucosylation of \u03b1-1-acid glycoprotein (AGP) in pancreatic cancer","volume":"132","author":"Balma\u00f1a","year":"2016","journal-title":"J. Proteome"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0675","first-page":"559","article-title":"Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer","volume":"56","author":"Park","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0680","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cld.2020.07.001","article-title":"Role of biomarkers and biopsy in hepatocellular carcinoma","volume":"24","author":"Chen","year":"2020","journal-title":"Clin. Liver Dis."},{"issue":"10504","key":"10.1016\/j.bbcan.2026.189603_bb0685","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0690","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41419-023-06027-0","article-title":"FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189603_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217643","article-title":"FUT2-dependent fucosylation of LAMP1 promotes the apoptosis of colorectal cancer cells by regulating the autophagy-lysosomal pathway","volume":"619","author":"Guo","year":"2025","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0700","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ceb.2003.08.002","article-title":"Glycan-dependent leukocyte adhesion and recruitment in inflammation","volume":"15","author":"Lowe","year":"2003","journal-title":"Curr. Opin. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0705","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.chembiol.2018.02.005","article-title":"Unmasking Fucosylation: from cell adhesion to immune system regulation and diseases","volume":"25","author":"Li","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0710","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4251\/wjgo.v15.i7.1119","article-title":"Core fucosylation and its roles in gastrointestinal glycoimmunology","volume":"15","author":"Zhang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0715","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070965","article-title":"Targeting cancer stem cells in triple-negative breast cancer","volume":"11","author":"Park","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0720","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0725","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0730","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189603_bb0735","doi-asserted-by":"crossref","first-page":"13638","DOI":"10.1074\/jbc.M802027200","article-title":"Roles of Pofut1 and O-fucose in mammalian notch signaling","volume":"283","author":"Stahl","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0740","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwae047","article-title":"Analysis of endogenous NOTCH1 from POFUT1 S162L patient fibroblasts reveals the importance of the O-fucose modification on EGF12 in human development","volume":"34","author":"Matsumoto","year":"2024","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0745","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.0702846105","article-title":"The O-fucose glycan in the ligand-binding domain of Notch1 regulates embryogenesis and T cell development","volume":"105","author":"Ge","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.bbcan.2026.189603_bb0750","doi-asserted-by":"crossref","first-page":"13638","DOI":"10.1074\/jbc.M802027200","article-title":"Roles of Pofut1 and <i>O<\/i>\u2212fucose in mammalian notch signaling","volume":"283","author":"Stahl","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189603_bb0755","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1158\/0008-5472.CAN-05-1069","article-title":"High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival","volume":"65","author":"Reedijk","year":"2005","journal-title":"Cancer Res."},{"issue":"44","key":"10.1016\/j.bbcan.2026.189603_bb0760","doi-asserted-by":"crossref","first-page":"eado8275","DOI":"10.1126\/sciadv.ado8275","article-title":"Inhibition of notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer","volume":"10","author":"Shen","year":"2024","journal-title":"Sci. Adv."},{"issue":"38","key":"10.1016\/j.bbcan.2026.189603_bb0765","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101592118","article-title":"Therapeutic inhibition of USP9x-mediated notch signaling in triple-negative breast cancer","volume":"118","author":"Jaiswal","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0770","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/onco.13911","article-title":"First-in-human, first-in-class, phase I trial of the Fucosylation inhibitor SGN-2FF in patients with advanced solid tumors","volume":"26","author":"Do","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189603_bb0775","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-4005","article-title":"Understanding the mechanism of 2FF-induced immune modulation","volume":"76","author":"Field","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0780","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1038\/s41598-017-11911-9","article-title":"Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0785","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1878-0261.12163","article-title":"Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1\/2 and p38 MAPK activation","volume":"12","author":"Carrascal","year":"2018","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0790","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-19-0500","article-title":"Therapeutic and prophylactic antitumor activity of an Oral inhibitor of Fucosylation in spontaneous mammary cancers","volume":"19","author":"Disis","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb0795","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molmed.2008.06.002","article-title":"Sialic acids in human health and disease","volume":"14","author":"Varki","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189603_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104330","article-title":"Sialylated glycoproteins and sialyltransferases in digestive cancers: mechanisms, diagnostic biomarkers, and therapeutic targets","volume":"197","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0805","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/glycob\/2.1.25","article-title":"Diversity in the sialic acids","volume":"2","author":"Varki","year":"1992","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0810","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2741\/e396","article-title":"Sialyltransferases functions in cancers","volume":"4","author":"Harduin-Lepers","year":"2012","journal-title":"Front. Biosci. (Elite Ed.)"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0815","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.bbagen.2014.06.006","article-title":"Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression","volume":"1840","author":"Dall\u2019Olio","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2026.189603_bb0820","series-title":"Essentials of Glycobiology","first-page":"631","article-title":"Glycosylation Changes in Cancer","author":"Bellis","year":"2022"},{"issue":"51","key":"10.1016\/j.bbcan.2026.189603_bb0825","doi-asserted-by":"crossref","first-page":"23633","DOI":"10.1021\/jacs.2c11094","article-title":"Photoproximity labeling of Sialylated glycoproteins (GlycoMap) reveals sialylation-dependent regulation of ion transport","volume":"144","author":"Meyer","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0830","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","article-title":"Insights into the role of sialylation in cancer progression and metastasis","volume":"124","author":"Dobie","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189603_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217713","article-title":"CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer","volume":"622","author":"Tang","year":"2025","journal-title":"Cancer Lett."},{"issue":"5\u20136","key":"10.1016\/j.bbcan.2026.189603_bb0840","first-page":"333","article-title":"Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125","volume":"7","author":"Szymendera","year":"1986","journal-title":"Tumour Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0845","article-title":"Robust Glycoproteomics platform reveals a tetra-antennary site-specific glycan capping with Sialyl-Lewis antigen for early detection of gastric cancer","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189603_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak","year":"2023","journal-title":"Mol. Asp. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0855","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2022.11.014","article-title":"Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma","volume":"56","author":"Wu","year":"2023","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0860","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02894259","article-title":"Clinical usefulness of alterations in sialic acid, sialyl transferase and sialoproteins in breast cancer","volume":"19","author":"Raval","year":"2004","journal-title":"Indian J. Clin. Biochem."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0865","first-page":"176","article-title":"Breast cancer associated mucin: a review","volume":"25","author":"Segal-Eiras","year":"1997","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0870","article-title":"The tumour Glyco-code: sialylation as a mediator of stromal cell immunosuppression in the tumour microenvironment","volume":"55","author":"O\u2019Neill","year":"2025","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0875","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/glycob\/cwn095","article-title":"A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression","volume":"18","author":"Abd Hamid","year":"2008","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb0880","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071446","article-title":"Glycosylation and its role in immune checkpoint proteins: from molecular mechanisms to clinical implications","volume":"12","author":"Liu","year":"2024","journal-title":"Biomedicines"},{"issue":"6828","key":"10.1016\/j.bbcan.2026.189603_bb0890","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0895","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020289","article-title":"The potential of Siglecs and sialic acids as biomarkers and therapeutic targets in tumor immunotherapy","volume":"16","author":"Feng","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189603_bb0900","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fonc.2019.00380","article-title":"Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks","volume":"9","author":"Peixoto","year":"2019","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189603_bb0905","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.18632\/oncotarget.8155","article-title":"Hallmarks of glycosylation in cancer","volume":"7","author":"Munkley","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0910","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1172\/JCI120612","article-title":"Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells","volume":"128","author":"Stanczak","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb0915","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0920","doi-asserted-by":"crossref","first-page":"1183285","DOI":"10.3389\/fimmu.2023.1183285","article-title":"The biological roles of CD24 in ovarian cancer: old story, but new tales","volume":"14","author":"Gu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189603_bb0925","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3389\/fimmu.2020.01324","article-title":"Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10","volume":"11","author":"Yin","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb0930","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"39","key":"10.1016\/j.bbcan.2026.189603_bb0935","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202502758","article-title":"Signal transducer nanoparticles enable Siglec-10\/G blockade immunotherapy for breast cancer treatment","volume":"37","author":"Meng","year":"2025","journal-title":"Adv. Mater."},{"issue":"26","key":"10.1016\/j.bbcan.2026.189603_bb0940","article-title":"Nano-LYTACs for degradation of membrane proteins and inhibition of CD24\/Siglec-10 signaling pathway","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189603_bb0945","article-title":"Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis","volume":"29","author":"Liu","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb0950","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312929121","article-title":"Siglec-15\/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb0955","article-title":"Osteoclast-derived apoptotic bodies inhibit naive CD8(+) T cell activation via Siglec15, promoting breast cancer secondary metastasis","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189603_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155472","article-title":"Sialylated immunoglobulins for the treatment of Immuno-inflammatory diseases","volume":"21","author":"Markina","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189603_bb0965","doi-asserted-by":"crossref","first-page":"1402000","DOI":"10.3389\/fimmu.2024.1402000","article-title":"IgG sialylation occurs in B cells pre antibody secretion","volume":"15","author":"Werner","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb0970","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/JLB.3MA0522-731R","article-title":"Divergent Golgi trafficking limits B cell-mediated IgG sialylation","volume":"112","author":"Glendenning","year":"2022","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb0975","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.7150\/thno.53961","article-title":"Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0980","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1953220","article-title":"The therapeutic potential of sialylated Fc domains of human IgG","volume":"13","author":"Pleass","year":"2021","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0985","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.immuni.2024.10.002","article-title":"Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease","volume":"58","author":"Chakraborty","year":"2025","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb0990","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13058-025-02052-3","article-title":"Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis","volume":"27","author":"Hu","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189603_bb0995","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1488668","article-title":"Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes","volume":"14","author":"Lustig","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb1000","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tips.2025.07.013","article-title":"Targeting glycosylation to enhance tumor immunotherapy","volume":"46","author":"Zhu","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2026.189603_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123855","article-title":"Glycosylated proteins with abnormal glycosylation changes are potential biomarkers for early diagnosis of breast cancer","volume":"236","author":"Chang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189603_bb1010","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216796120","article-title":"O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation","volume":"120","author":"Zhu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb1015","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/eji.202048543","article-title":"Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"42","key":"10.1016\/j.bbcan.2026.189603_bb1020","article-title":"ST6GAL1-mediated sialylation stabilizes PD-L1 and drives immunosuppressive tumor microenvironment in colorectal cancer","volume":"12","author":"Xu","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/0008-5472.CAN-12-2418","article-title":"Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease","volume":"73","author":"Dalotto-Moreno","year":"2013","journal-title":"Cancer Res."},{"issue":"37","key":"10.1016\/j.bbcan.2026.189603_bb1030","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CJI.0000000000000465","article-title":"Enhancing the anti-tumor potency of a novel Siglec-15 antibody by engineering its fc-mediated effector functions","volume":"46","author":"Ding","year":"2023","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10719-021-10001-3","article-title":"Serum N-glycan profiles differ for various breast cancer subtypes","volume":"38","author":"Vreeker","year":"2021","journal-title":"Glycoconj. J."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41598-023-51021-3","article-title":"N-glycan profiling of tissue samples to aid breast cancer subtyping","volume":"14","author":"Benesova","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189603_bb1050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbpa.2017.12.005","article-title":"Advances in mass spectrometry imaging coupled to ion mobility spectrometry for enhanced imaging of biological tissues","volume":"42","author":"Sans","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb1055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1515\/cclm-2018-0379","article-title":"Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey","volume":"57","author":"Wang","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb1060","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/elps.201100703","article-title":"Comparing MALDI-MS, RP-LC-MALDI-MS and RP-LC-ESI-MS glycomic profiles of permethylated N-glycans derived from model glycoproteins and human blood serum","volume":"33","author":"Hu","year":"2012","journal-title":"Electrophoresis"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb1065","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1021\/pr900322g","article-title":"Mass spectrometry (LC-MS\/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers","volume":"8","author":"Whelan","year":"2009","journal-title":"J. Proteome Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb1070","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1074\/mcp.M116.059816","article-title":"N-glycan MALDI imaging mass spectrometry on formalin-fixed paraffin-embedded tissue enables the delineation of ovarian cancer tissues","volume":"15","author":"Everest-Dass","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1075","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800014","article-title":"Increases in tumor N-glycan Polylactosamines associated with advanced HER2-positive and triple-negative breast cancer tissues","volume":"13","author":"Scott","year":"2019","journal-title":"Proteomics Clin. Appl."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb1080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mas.21725","article-title":"Applications and continued evolution of glycan imaging mass spectrometry","volume":"42","author":"McDowell","year":"2023","journal-title":"Mass Spectrom. Rev."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb1085","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/hep.26262","article-title":"Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis","volume":"57","author":"Kamiyama","year":"2013","journal-title":"Hepatology"},{"issue":"6\u20137","key":"10.1016\/j.bbcan.2026.189603_bb1090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10719-014-9548-4","article-title":"Overexpression of \u03b12,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis","volume":"31","author":"Patil","year":"2014","journal-title":"Glycoconj. J."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250747","article-title":"Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens","volume":"16","author":"Sakata-Matsuzawa","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189603_bb1100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ebiom.2018.01.026","article-title":"Salivary Glycopatterns as potential biomarkers for screening of early-stage breast cancer","volume":"28","author":"Liu","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt.3403","article-title":"Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides","volume":"34","author":"Sun","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb1110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/19420862.2015.1117719","article-title":"Glycan analysis of therapeutic glycoproteins","volume":"8","author":"Zhang","year":"2016","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00216-024-05686-y","article-title":"Inter-tissue glycan heterogeneity: site-specific glycoform analysis of mouse tissue N-glycoproteomes using MS1-based glycopeptide detection method assisted by lectin microarray","volume":"417","author":"Nagai-Okatani","year":"2025","journal-title":"Anal. Bioanal. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb1120","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1021\/pr201059g","article-title":"Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS\/MS and tissue microarray","volume":"11","author":"Zhu","year":"2012","journal-title":"J. Proteome Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189603_bb1125","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.1021\/acsnano.4c16988","article-title":"Fully integrated centrifugal microfluidics for rapid exosome isolation, glycan analysis, and point-of-care diagnosis","volume":"19","author":"Zhao","year":"2025","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189603_bb1130","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1039\/c2cs35435g","article-title":"Binding sugars: from natural lectins to synthetic receptors and engineered neolectins","volume":"42","author":"Arnaud","year":"2013","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12916-025-03871-z","article-title":"Development a glycosylated extracellular vesicle-derived miRNA signature for early detection of esophageal squamous cell carcinoma","volume":"23","author":"Chen","year":"2025","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41598-023-27634-z","article-title":"Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering","volume":"13","author":"Saunders","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb1145","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1021\/acssensors.4c03666","article-title":"A Glycosyl-imprinted sensor used for accurate classification and quantification of breast cancer-derived exosomes by electrochemiluminescence detection of two glycoproteins at dual potentials","volume":"10","author":"Luo","year":"2025","journal-title":"ACS Sens."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050395","article-title":"Benefits and pitfalls of a glycosylation inhibitor Tunicamycin in the therapeutic implication of cancers","volume":"13","author":"Banerjee","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189603_bb1155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/08923973.2021.1979035","article-title":"Inhibition of O-glycosylation aggravates GalN\/LPS-induced liver injury through activation of ER stress","volume":"43","author":"Xu","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189603_bb1160","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrm3383","article-title":"Vertebrate protein glycosylation: diversity, synthesis and function","volume":"13","author":"Moremen","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1165","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1074\/jbc.M510893200","article-title":"Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189603_bb1170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178448","article-title":"Enhancing antitumor efficacy of MUC1 mRNA Nano-vaccine by CTLA-4 siRNA-mediated immune checkpoint modulation in triple negative breast Cancer mice model","volume":"26","author":"Monfaredan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 4","key":"10.1016\/j.bbcan.2026.189603_bb1175","article-title":"MUC1 aptamer-functionalized chitosan nanoparticles: targeted delivery platforms for synergistic cancer therapy and multidrug resistance overcoming","volume":"319","author":"Hsu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1180","article-title":"Exploiting human fucosyltransferase 8 allostery with a covalent inhibitor for core fucosylation suppression","volume":"17","author":"Jiang","year":"2026","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12967-024-05039-4","article-title":"Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease-specific haptoglobin N-glycosylation","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189603_bb1195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006464","article-title":"Predictive biomarkers for PD-1\/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data","volume":"11","author":"So","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.106070","article-title":"Diagnostic potential of Tn-MUC1 in breast cancer: a novel Immunohistochemical marker reflecting tumor progression","volume":"106","author":"Shimizu","year":"2026","journal-title":"Lab. Investig."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb1205","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120600","article-title":"NF-\u03baB signaling is regulated by Fucosylation in metastatic breast cancer cells","volume":"8","author":"Doud","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-025-00693-w","article-title":"Bisecting GlcNAc enhances CD8(+) T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1","volume":"14","author":"Ren","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/1535-7163.MCT-24-0666","article-title":"DS-3939a: a TA-MUC1-directed antibody-drug conjugate with broad antitumor activity","volume":"25","author":"Takano","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031406","article-title":"GT-00AxIL15, a novel tumor-targeted IL-15-based Immunocytokine for the treatment of TA-MUC1-positive solid tumors: preclinical in vitro and in vivo Pharmacodynamics and biodistribution studies","volume":"25","author":"Gellert","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189603_bb1225","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1158\/1535-7163.MCT-19-0826","article-title":"An antibody-drug conjugate targeting MUC1-associated carbohydrate CA6 shows promising antitumor activities","volume":"19","author":"Nicolazzi","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189603_bb1230","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3892\/ijo.2016.3386","article-title":"Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I\/II clinical trial","volume":"48","author":"Antonilli","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189603_bb1235","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.1021\/ja211725s","article-title":"A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy","volume":"134","author":"Huang","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189603_bb1240","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1021\/jacs.2c12843","article-title":"MUC1 Glycopeptide vaccine modified with a GalNAc Glycocluster targets the macrophage galactose C-type lectin on dendritic cells to elicit an improved humoral response","volume":"145","author":"Gabba","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbcan.2026.189603_bb1245","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189603_bb1250","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.7150\/thno.38236","article-title":"Preclinical evaluation of an (111)in\/(225)ac theranostic targeting transformed MUC1 for triple negative breast cancer","volume":"10","author":"Kelly","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40425-018-0347-5","article-title":"CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation","volume":"6","author":"Bajgain","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7150\/thno.21278","article-title":"A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189603_bb1265","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1158\/1078-0432.CCR-11-1151","article-title":"Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer","volume":"17","author":"Ibrahim","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1270","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2409","article-title":"Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer","volume":"11","author":"Pegram","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"Pt 4","key":"10.1016\/j.bbcan.2026.189603_bb1275","article-title":"A bispecific antibody targeting the Ig domains of Siglec-E displays enhanced antitumor effects","volume":"281","author":"Zhao","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189603_bb1280","first-page":"A803","article-title":"A Phase 1\/2 dose escalation\/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a Bi-sialidase fusion protein, in advanced cancer (Glimmer-01)","volume":"10","author":"Sharma","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189603_bb1285","first-page":"7","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189603_bb1290","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41419-024-06704-8","article-title":"LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6382","key":"10.1016\/j.bbcan.2026.189603_bb1295","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1300","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189603_bb1305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-012-0309-9","article-title":"Roles for major histocompatibility complex glycosylation in immune function","volume":"34","author":"Ryan","year":"2012","journal-title":"Semin. Immunopathol."},{"issue":"6679","key":"10.1016\/j.bbcan.2026.189603_bb1310","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.adg1955","article-title":"Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape","volume":"383","author":"Sharma","year":"2024","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189603_bb1315","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","article-title":"Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers","volume":"10","author":"Song","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189603_bb1320","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941666","article-title":"PD-L1 amino acid position 88 represents a hotspot for PD-L1 stability with relevance for PD-L1 inhibition","volume":"12","author":"Claa\u00df","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:30:53Z","timestamp":1785072653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":264,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26000752"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189603","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role and therapeutic potential of protein glycosylation in the immune regulation of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189603"}}